Home > Oncology > 4-year PACIFIC data hold strong in NSCLC

4-year PACIFIC data hold strong in NSCLC

Presented By
Dr. Camille Hertzka , AstraZeneca
Journal
Physician's Weekly
Conference
ESMO Virtual Congress 2020
Trial
Phase 3, PACIFIC
At the ESMO Virtual Congress 2020 held 19-21 September, 2020, updated post-hoc findings from the PACIFIC Phase III trial confirmed that with a 4-year follow-up, durvalumab leads to a  sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit in patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT) [1]. Our journalist interviewed Dr. Camille Hertzka, US Head of Medical Affairs Oncology at AstraZeneca, to discuss the implications. The Phase III PACIFIC trial (NCT02125461) was a randomized, double-blinded, placebo-controlled, multi-center study (n=713) of durvalumab as a treatment in all-comer NSCLC patients, reg...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on